I. Monnet
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
-
- Lung Cancer Treatments and Mutations 63
- Occupational and environmental lung diseases 34
- Lung Cancer Diagnosis and Treatment 17
- Brain Metastases and Treatment 8
- Oncology 42
- Cancer Immunotherapy and Biomarkers 24
- Lung Cancer Research Studies 12
- COVID-19 and healthcare impacts 3
- Co-authors
- CHRISTOS CHOUAID (60 shared papers)Rodrigo Arriagada (6 shared papers)Thierry Le Chevalier (7 shared papers)Pierre Chomy (4 shared papers)Marie Wislez (23 shared papers)Fabrice Barlési (16 shared papers)Jacques L. Cadranel (23 shared papers)Henri Berard (13 shared papers)
- Journals
- Annals of Oncology (36 papers)Lung Cancer (20 papers)Journal of Thoracic Oncology (20 papers)Journal of Clinical Oncology (11 papers)European Journal of Cancer (9 papers)
- Partner nations
- FranceUnited StatesNetherlands
In The Last Decade
I. Monnet
210 papers receiving 9.9k citations
I. Monnet's Hit Papers
Peers
Comparison fields: 5 of 84
- Pulmonary and Respiratory Medicine 5.0k
- Oncology 1.9k
- Geriatrics and Gerontology 182
- Internal Medicine 77
- Cancer Research 200
Countries citing papers authored by I. Monnet
This map shows the geographic impact of I. Monnet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Monnet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Monnet more than expected).
Fields of papers citing papers by I. Monnet
This network shows the impact of papers produced by I. Monnet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Monnet. The network helps show where I. Monnet may publish in the future.
Co-authors
The 25 scholars most cited alongside I. Monnet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 223 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Hit paper breakdown → | 2016 | 806 |
| 2 | Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial Hit paper breakdown → | 2015 | 765 |
| 3 | 1995 | 448 | |
| 4 | Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial Hit paper breakdown → | 2019 | 364 |
| 5 | 2015 | 313 | |
| 6 | 2016 | 304 | |
| 7 | Targeting RET in Patients With RET -Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry Hit paper breakdown → | 2017 | 301 |
| 8 | 2015 | 262 | |
| 9 | 2021 | 242 | |
| 10 | COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer Hit paper breakdown → | 2022 | 229 |
| 11 | 2020 | 224 | |
| 12 | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 Hit paper breakdown → | 2022 | 211 |
| 13 | 1993 | 201 | |
| 14 | 2011 | 196 | |
| 15 | 2012 | 186 | |
| 16 | 2013 | 172 | |
| 17 | 2019 | 164 | |
| 18 | 2018 | 154 | |
| 19 | 2014 | 144 | |
| 20 | 2013 | 139 |
About I. Monnet
I. Monnet is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Geriatrics and Gerontology, Internal Medicine and Economics and Econometrics, having authored 223 papers that have together received 10.2k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (63 papers), Occupational and environmental lung diseases (34 papers), Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Diagnosis and Treatment (17 papers), Lung Cancer Research Studies (12 papers), Brain Metastases and Treatment (8 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and COVID-19 and healthcare impacts (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (5.0k citations), Oncology (1.9k citations), Geriatrics and Gerontology (182 citations), Internal Medicine (77 citations) and Cancer Research (200 citations). I. Monnet has collaborated with scholars based in France, United States and Netherlands. Frequent co-authors include CHRISTOS CHOUAID, Rodrigo Arriagada, Thierry Le Chevalier, Pierre Chomy, Marie Wislez, Fabrice Barlési, Jacques L. Cadranel, Henri Berard, Martine Antoine and Simone Benhamou. Their work appears in journals such as Annals of Oncology, Lung Cancer, Journal of Thoracic Oncology, Journal of Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.